Molecule profile · Module 9
MOTS-c — evidence and research limits
MOLECULE PROFILE
- Evidence summary
- Preclinical evidence
- Lee and colleagues reported preclinical metabolic findings. Reynolds and colleagues combined measurements of endogenous MOTS-c after human exercise with experiments administering it to mice. The human observations do not demonstrate that injecting MOTS-c reproduces exercise benefits in people. CB4211 is a modified analogue and requires separate evidence. The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
- Regulatory status varies by jurisdiction
- The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Identity and mechanism
MOTS-c is discussed as a mitochondrial-derived peptide involved in experimental metabolic signaling. The course separates its proposed biological origin from claims that an administered formulation reaches a particular compartment or reproduces normal exposure. Metabolic mechanisms provide research questions; they are not a demonstrated clinical indication.
What the evidence supports
Lee and colleagues reported preclinical metabolic findings. Reynolds and colleagues combined measurements of endogenous MOTS-c after human exercise with experiments administering it to mice. The human observations do not demonstrate that injecting MOTS-c reproduces exercise benefits in people. CB4211 is a modified analogue and requires separate evidence.
The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
Regulatory context
The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Safety and uncertainty
Human endogenous measurement does not characterize the safety of exogenous administration. Human safety cannot be inferred from a cell result, a product name, or lack of events in a small report. These educational adaptations do not provide an administration protocol.
Sport and anti-doping status
The WADA 2026 Prohibited List names MOTS-c among AMP-activated protein kinase (AMPK) activators in section S4.4.1, metabolic modulators, prohibited at all times (in and out of competition). This is an anti-doping classification, separate from clinical evidence, product quality and regulatory approval. Medical supervision, a prescription or an approved indication does not by itself permit use in sport; any exemption for a documented medical condition is a separate decision by the competent anti-doping organization. The List is revised each year, so check the List in force on the relevant date.
Continue learning
Explore Module 9 in PEPTIDE Academy for the full evidence discussion.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. DOI: 10.1016/j.cmet.2015.02.009. PMID: 25738459.DOI 10.1016/j.cmet.2015.02.009 · PMID 25738459
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. DOI: 10.1038/s41467-020-20790-0. PMID: 33473109.DOI 10.1038/s41467-020-20790-0 · PMID 33473109
- World Anti-Doping Agency. International Standard: Prohibited List 2026 (in effect from 1 January 2026). Checked 19 October 2026.
Related resources
Molecule profile · Module 9
Epitalon
The research discussed for Epitalon concerns telomerase activity and telomere length in cultured human somatic cells. Human origin of the cells does not turn a culture experiment into a human treatment trial. Epitalon and epithalamin are different interventions and should not share efficacy or safety claims without direct evidence.
Molecule profile · Module 3
AOD-9604
AOD-9604 is a modified fragment related to the C-terminal region of growth hormone. The rationale discussed in the course concerns metabolic effects attributed to the fragment, rather than assuming that it reproduces every action of full-length growth hormone. Identity, formulation, and route must be specified when comparing reports.
Molecule profile · Module 6
BPC-157
BPC-157 has been investigated in experimental tissue-repair models. The course examines tendon-cell survival, migration, and growth from explants as mechanistic findings. Those endpoints can help formulate hypotheses about repair; they do not directly measure recovery from a human tendon injury or return to sport.